Researchers from Roswell Park will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30.
Roswell Park Comprehensive Cancer Center achieved "textbook" positive outcomes for 90% of 150 consecutive minimally invasive esophagectomies (RAMIE) performed between 2020-2024, as reported in a study in the Journal of Gastrointestinal Surgery.
Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to a preclinical study led by Roswell Park. Results of the study, led by Sayan Chakraborty, PhD, Assistant Professor of Oncology at Roswell Park, appear in Advanced Science.
Thomas B. Tomasi Jr., MD, PhD, who led Roswell Park as President and CEO from 1986-1996, died March 23, 2025, at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers.
A clinical research study led by Roswell Park experts outlines a new way to measure pain in cancer patients and treat it effectively without opioids. The new study advances the goal of better managing cancer pain by incorporating both non-invasive brain imaging technology and virtual reality (VR).
Cancer surgery leaders from Roswell Park will share their expertise with other cancer surgeons from around the world during the annual meeting of the Society of Surgical Oncology at the Tampa Convention Center March 27-29.
Roswell Park’s Intensive Care Unit Earns National Recognition for Exceptional Patient Outcomes
Roswell Park Named One of Only 37 Optum Cancer Centers of Excellence for Adult and Pediatric Patients
BUFFALO, N.Y. — Today, on a call with officials from the American Nurses Credentialing Center (ANCC), nurses from teams across Roswell Park Comprehensive Cancer Center learned that they earned a prestigious distinction: Magnet® Recognition for nursing excellence. The designation follows an in-depth review by the ANCC, and signifies that Roswell Park nurses have met stringent standards for nursing excellence in patient care delivery.
A new study published in the journal Nature Communications, led by Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, of Roswell Park, highlights the therapeutic impact of CDK2 inhibitors as treatment for cancers including some breast and pancreatic tumors.
Roswell Park experts will share new discoveries and insights at the 2025 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) Feb. 12-15 in Honolulu.
Researchers at Albert Einstein College of Medicine, Roswell Park Comprehensive Cancer Center and the Icahn School of Medicine at Mount Sinai have found that bacterial vaginosis consists of two distinct subtypes — one of which significantly increases the risk of developing chlamydia infections
Researchers at Roswell Park Comprehensive Cancer Center have identified a cause of resistance to doxorubicin in triple-negative breast cancer. The team’s new study in Scientific Reports points to a new strategy for overcoming this resistance to treatment, using drugs known as IMPDH2 inhibitors.
As the year comes to a close, Roswell Park Comprehensive Cancer Center honors the 143 physicians across 35 specialties named to Buffalo Spree magazine’s Top Doctors list for 2025. The annual list is compiled through surveys submitted by Western New York physicians.
A team of researchers at Roswell Park , led by Dhyan Chandra, PhD, has discovered a new therapeutic target for neuroendocrine prostate cancer, a rare and hard-to-treat form of prostate cancer. Their findings, newly published in the journal Oncogene, suggest that a set of processes known as the mitochondrial unfolded protein response, could be an Achilles’ heel for this often-deadly cancer type, and may point the way to a new treatment approach.
Governor Kathy Hochul today celebrated the opening of the Roswell Park GMP Engineering and Cell Manufacturing Facility, New York's first cell and gene therapy hub, located at Roswell Park Comprehensive Cancer Center in Buffalo. The $98 million facility will create new jobs, help to support the research and development of life-saving cell and gene therapies at Roswell, significantly grow its well-established research capabilities, and establish Roswell as one of the premier cell therapy discovery and development institutions in the nation. The expansion also realizes Governor Hochul’s 2023 State of the State commitment to bolster the state’s leadership in the fast-growing CGT sector through establishment of an Upstate cell and gene therapy hub to catalyze its growth in western NY. The GEM facility meets U.S. FDA Good Manufacturing Practice standards for manufacture of clinical cell therapy products, positioning the Roswell Park team to be a multifaceted resource for patients, care teams
A study led by Roswell Park provides new insight into the complex interactions of the “tumor-immune-gut axis,” and its role in influencing immunotherapy responses in patients with recurrent ovarian cancer. Newly published in Nature Communications, the findings emphasize the role of the patient’s microbiome — the collection of microorganisms in the body —and lay the groundwork for future clinical trials aimed at improving treatment outcomes.
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.
Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.
The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right